Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review

Tabi-Amponsah, Adwoa Dansoa
Stewart, Sarah
Hosie, Graham
Stamp, Lisa K
Taylor, William J
Dalbeth, Nicola
Item type
Journal Article
Degree name
Journal Title
Journal ISSN
Volume Title

Urate-lowering therapies for the management of gout lead to a reduction in serum urate levels, monosodium urate crystal deposition, and the clinical features of gout, including painful and disabling gout flares, chronic gouty arthritis, and tophi. Thus, disease remission is a potential goal of urate-lowering therapy. In 2016, preliminary gout remission criteria were developed by a large group of rheumatologists and researchers with expertise in gout. The preliminary gout remission criteria were defined as: serum urate < 0.36 mmol/L (6 mg/dL); an absence of gout flares; an absence of tophi; pain due to gout < 2 on a 0–10 scale; and a patient global assessment < 2 on a 0–10 scale over a 12-month period. In this critical review, we describe the development of the preliminary gout remission criteria, the properties of the preliminary gout remission criteria, and clinical studies of gout remission in people taking urate-lowering therapy. We also describe a future research agenda for gout remission.

1115 Pharmacology and Pharmaceutical Sciences , 3214 Pharmacology and pharmaceutical sciences
Pharmaceuticals, ISSN: 1424-8247 (Print), MDPI AG, 16(6). doi: 10.3390/ph16060779
Rights statement